DPP4 and COVID-19: These repurposed drugs could be considered as effective TLR4 antagonists for COVID patients experiencing a cytokine storm, especially given that DPP-4 is expressed in almost all the major immune cells (macrophages, dendritic cells, T cells, B cells, NK cells) contributing to COVID-19 immunopathology, especially the cytokine storm [79].